{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-073937","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.921869+00:00","generated_at":"2026-05-23T19:42:01.804750+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Viridian appoints Jeff Ajer to board; grants stock options to 14 new employees","bullets":["Jeff Ajer, former BioMarin CCO with 25+ years rare disease experience, appointed to VRDN board effective April 7, 2025.","Ajer led launches of 5 brands at BioMarin; will support veligrotug BLA submission and potential commercial launch.","Compensation Committee approved inducement grants of options for 220,750 shares to 14 new employees on April 1, 2025.","Options vest over 4 years (25% at one-year anniversary, then monthly), exercise price equals closing price on grant date.","Appointment strengthens board as Viridian advances veligrotug and FcRn portfolio toward regulatory milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-073937","json":"https://secwatch.observer/filing/0001193125-25-073937.json","markdown":"https://secwatch.observer/filing/0001193125-25-073937.md","text":"https://secwatch.observer/filing/0001193125-25-073937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/0001193125-25-073937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/d875125d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:42:01.804750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a702b4dfaa","claim":"Jeff Ajer was appointed as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On April 2, 2025, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”), appointed Jeff Ajer to serve as a Class I director of the Company, effective as of April 7, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/0001193125-25-073937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}